BACKGROUND: More active therapies are needed for older and unfit patients with chronic lymphocytic leukemia (CLL) who are not eligible for chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab. The phosphyotidylinositol-3-kinase δ inhibitor idelalisib is effective in patients with treatment-naive and relapsed/refractory CLL as monotherapy and in combination with rituximab, but it can be associated with treatment-limiting adverse events, particularly diarrhea/colitis. The outcomes for patients who cease treatment for adverse events have not been previously described. METHODS: The authors analyzed long-term follow-up data from 40 treatment-naïve patients aged ≥65 years who received treatment at The University of Texas MD Anderson Cancer Center on a phase 2 study of idelalisib plus rituximab for CLL. RESULTS: In patients who permanently ceased treatment because of toxicity, the time to subsequent disease progression was analyzed according to baseline characteristics. Fifteen patients permanently ceased therapy (PCT) because of toxicity (PCTTOX ), most commonly diarrhea/colitis (n = 7), at a median of 11 months after commencing treatment. PCTTOX was associated with a higher risk of subsequent disease progression (hazard ratio, 6.61; 95% confidence interval, 1.77-16.15) relative to that observed in patients who remained on therapy. Ten patients subsequently progressed, and 7 required salvage therapy; 5 patients remained progression-free at a median of 23.3 months (range, 8.5-28.6 months). Patients who were positive for ζ-associated protein-70 had more rapid disease progression after treatment cessation (P = .048). There were no CLL-related deaths. CONCLUSIONS: PCTTOX is the major determinant of PFS in patients who receive first-line idelalisib-based treatment. However, a subgroup of patients with favorable biologic characteristics has prolonged PFS, even after PCTTOX . The absence of CLL-related deaths indicates that salvage treatment is generally successful after PCTTOX . Cancer 2016;122:2505-11.
BACKGROUND: More active therapies are needed for older and unfit patients with chronic lymphocytic leukemia (CLL) who are not eligible for chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab. The phosphyotidylinositol-3-kinase δ inhibitor idelalisib is effective in patients with treatment-naive and relapsed/refractory CLL as monotherapy and in combination with rituximab, but it can be associated with treatment-limiting adverse events, particularly diarrhea/colitis. The outcomes for patients who cease treatment for adverse events have not been previously described. METHODS: The authors analyzed long-term follow-up data from 40 treatment-naïve patients aged ≥65 years who received treatment at The University of Texas MD Anderson Cancer Center on a phase 2 study of idelalisib plus rituximab for CLL. RESULTS: In patients who permanently ceased treatment because of toxicity, the time to subsequent disease progression was analyzed according to baseline characteristics. Fifteen patients permanently ceased therapy (PCT) because of toxicity (PCTTOX ), most commonly diarrhea/colitis (n = 7), at a median of 11 months after commencing treatment. PCTTOX was associated with a higher risk of subsequent disease progression (hazard ratio, 6.61; 95% confidence interval, 1.77-16.15) relative to that observed in patients who remained on therapy. Ten patients subsequently progressed, and 7 required salvage therapy; 5 patients remained progression-free at a median of 23.3 months (range, 8.5-28.6 months). Patients who were positive for ζ-associated protein-70 had more rapid disease progression after treatment cessation (P = .048). There were no CLL-related deaths. CONCLUSIONS:PCTTOX is the major determinant of PFS in patients who receive first-line idelalisib-based treatment. However, a subgroup of patients with favorable biologic characteristics has prolonged PFS, even after PCTTOX . The absence of CLL-related deaths indicates that salvage treatment is generally successful after PCTTOX . Cancer 2016;122:2505-11.
Authors: M Hallek; K Fischer; G Fingerle-Rowson; A M Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; P L Zinzani; F Caligaris-Cappio; J F Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; C M Wendtner; B F Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; M Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: V Goede; K Fischer; A Engelke; R Schlag; S Lepretre; L F C Montero; M Montillo; C Fegan; E Asikanius; K Humphrey; G Fingerle-Rowson; M Hallek Journal: Leukemia Date: 2015-01-30 Impact factor: 11.528
Authors: Susan M O'Brien; Nicole Lamanna; Thomas J Kipps; Ian Flinn; Andrew D Zelenetz; Jan A Burger; Michael Keating; Siddhartha Mitra; Leanne Holes; Albert S Yu; David M Johnson; Langdon L Miller; Yeonhee Kim; Roger D Dansey; Ronald L Dubowy; Steven E Coutre Journal: Blood Date: 2015-10-15 Impact factor: 22.113
Authors: Richard R Furman; Jeff P Sharman; Steven E Coutre; Bruce D Cheson; John M Pagel; Peter Hillmen; Jacqueline C Barrientos; Andrew D Zelenetz; Thomas J Kipps; Ian Flinn; Paolo Ghia; Herbert Eradat; Thomas Ervin; Nicole Lamanna; Bertrand Coiffier; Andrew R Pettitt; Shuo Ma; Stephan Stilgenbauer; Paula Cramer; Maria Aiello; Dave M Johnson; Langdon L Miller; Daniel Li; Thomas M Jahn; Roger D Dansey; Michael Hallek; Susan M O'Brien Journal: N Engl J Med Date: 2014-01-22 Impact factor: 91.245
Authors: Jennifer R Brown; John C Byrd; Steven E Coutre; Don M Benson; Ian W Flinn; Nina D Wagner-Johnston; Stephen E Spurgeon; Brad S Kahl; Celeste Bello; Heather K Webb; Dave M Johnson; Sissy Peterman; Daniel Li; Thomas M Jahn; Brian J Lannutti; Roger G Ulrich; Albert S Yu; Langdon L Miller; Richard R Furman Journal: Blood Date: 2014-03-10 Impact factor: 22.113
Authors: Klaus Okkenhaug; Antonio Bilancio; Géraldine Farjot; Helen Priddle; Sara Sancho; Emma Peskett; Wayne Pearce; Stephen E Meek; Ashreena Salpekar; Michael D Waterfield; Andrew J H Smith; Bart Vanhaesebroeck Journal: Science Date: 2002-07-18 Impact factor: 47.728
Authors: Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps Journal: Blood Date: 2008-01-23 Impact factor: 22.113
Authors: Elizabeth Clayton; Giuseppe Bardi; Sarah E Bell; David Chantry; C Peter Downes; Alexander Gray; Lisa A Humphries; David Rawlings; Helen Reynolds; Elena Vigorito; Martin Turner Journal: J Exp Med Date: 2002-09-16 Impact factor: 14.307
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640
Authors: Benjamin L Lampson; Haesook T Kim; Matthew S Davids; Jeremy S Abramson; Arnold S Freedman; Caron A Jacobson; Philippe A Armand; Robin M Joyce; Jon E Arnason; Laura Z Rassenti; Thomas J Kipps; Joshua Fein; Stacey M Fernandes; John R Hanna; David C Fisher; Jennifer R Brown Journal: Blood Adv Date: 2019-04-09
Authors: V Koneti Rao; Sharon Webster; Virgil A S H Dalm; Anna Šedivá; P Martin van Hagen; Steven Holland; Sergio D Rosenzweig; Andreas D Christ; Birgitte Sloth; Maciej Cabanski; Aniket D Joshi; Stefan de Buck; Julie Doucet; Danilo Guerini; Christoph Kalis; Ilona Pylvaenaeinen; Nicolas Soldermann; Anuj Kashyap; Gulbu Uzel; Michael J Lenardo; Dhavalkumar D Patel; Carrie L Lucas; Christoph Burkhart Journal: Blood Date: 2017-09-29 Impact factor: 22.113